Compare WKSP & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKSP | INTS |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 24.0M |
| IPO Year | N/A | 2023 |
| Metric | WKSP | INTS |
|---|---|---|
| Price | $1.37 | $0.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $9.25 | $2.25 |
| AVG Volume (30 Days) | 230.0K | ★ 1.4M |
| Earning Date | 03-26-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,286,679.00 | N/A |
| Revenue This Year | $135.39 | N/A |
| Revenue Next Year | $116.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 123.37 | N/A |
| 52 Week Low | $1.40 | $0.19 |
| 52 Week High | $9.10 | $2.50 |
| Indicator | WKSP | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 26.85 | 23.38 |
| Support Level | $1.40 | $0.34 |
| Resistance Level | $1.75 | $0.39 |
| Average True Range (ATR) | 0.17 | 0.02 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 12.84 | 3.99 |
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers. It operates in two reporting segments for financial reporting purposes: Hard Tonneau Covers and Soft Tonneau Covers. Geographically, the company operates in Canada, United States and Other Countries.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.